Q9999 Injection ustekinumab-aauz 1 milligrams
Also known as: ustekinumab biosimilar, IL-12/23 inhibitor, Rezurock
Injection of ustekinumab-aauz (Rezurock), a biosimilar to ustekinumab, administered at 1 milligram per dose.
In Plain Language
immune system medication; skin disease treatment; autoimmune blocker
Clinical Context
Used for moderate to severe plaque psoriasis and other TNF-mediated inflammatory conditions as biosimilar formulation.
RVU Information
CPT Q9999 does not have a physician work RVU assigned by CMS. Reimbursement for this code is determined by payer-specific fee schedules.
Billing & Documentation
Q-codes are temporary HCPCS codes used when no permanent code exists. Coverage and reimbursement vary by payer and region. Document the clinical indication and medical necessity. These codes may be replaced by permanent codes in future HCPCS updates.
Specialties
Frequently Asked Questions
What is CPT code Q9999?
CPT Q9999 (Injection ustekinumab-aauz 1 milligrams) is a Q Codes code. Injection of ustekinumab-aauz (Rezurock), a biosimilar to ustekinumab, administered at 1 milligram per dose.
Is Q9999 covered by insurance?
Q9999 is a temporary HCPCS code. Coverage varies by payer and may change when permanent codes are assigned. Used for moderate to severe plaque psoriasis and other TNF-mediated inflammatory conditions as biosimilar formulation.
When is CPT Q9999 used?
Used for moderate to severe plaque psoriasis and other TNF-mediated inflammatory conditions as biosimilar formulation.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against national data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.